Arvee Laboratories (India) Limited has informed the Exchange regarding Board meeting held on May 09, 2025.
ARVEE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Arvee Laboratories reported FY25 revenue from operations of ₹3,848.72 lakhs, up about 27% from ₹3,034.52 lakhs in FY24. Profit after tax more than doubled to ₹214.74 lakhs (FY24: ₹105.18 lakhs), and EPS rose to ₹1.95 from ₹0.95. However, Q4 performance was weak with PAT of just ₹6.92 lakhs versus ₹11.60 lakhs in Q4 FY24. Cash from operations collapsed to essentially nil at ₹(3.73) lakhs compared to ₹670.79 lakhs last year, even as profitability improved sharply. The board approved the financial results, noted an unmodified (clean) auditor opinion from Nirav Patel & Associates, approved the related party transaction statement, re-appointed internal auditors, and appointed Jalan Alkesh & Associates as Secretarial Auditor for five years.
Strong annual growth in revenue and profits is positive for shareholders, but the steep drop in operating cash flow and a weak Q4 could temper enthusiasm. The clean auditor opinion and stable auditor appointments are reassuring; near-term watchpoints are cash generation and working capital.